News
Three NIH Technology Transfer experts will be speaking at the Biotechnology Innovation Organization 2024 International Convention taking place in San Diego June 3-6, 2024 . Tara Kirby, Director of the NIH Office of Technology Transfer will be participating in the In and Out of This World: Partnering
Are you interested in achieving commercial success with NIH as a strategic partner? Michael Salgaller of the National Cancer Institute (NCI) is leading a workshop at the MedInvest Oncology Investor Conference on how to partner with NIH to bring one of over 2,000 available inventions to market. This
Register to attend a free webinar to assess co-developing an NCI technology. Attendees will learn about new antibodies developed at the National Cancer Institute in the laboratory of David Fitzgerald, Ph.D. Dr. Fitzgerald and his team established that using one of the antibodies, 40H3, as an
Inventors at the National Human Genome Research Institute (NHGRI) discovered that N-acetylmannosamine (ManNAc) can be used for therapeutic purposes. ManNAc therapy given orally shows long-term safety and biochemical efficacy. ManNAc is a small uncharged physiological molecule that crosses membranes